The global head and neck cancer diagnostic market size was estimated to be USD 5.48 billion in 2023 and is expected to reach at USD 18.99 billion by 2034 with a CAGR of 11.96% during the forecast period 2024-2034. Increasing prevalence of head & neck cancer, growing geriatric population, surge in number of diagnostic procedures for head & neck cancer, availability of several diagnostic techniques for head & neck cancer, rising initiatives taken by research institutes to increase awareness regarding head & neck cancer, increasing technological advancements, growing demand for early diagnosis of the disease, and surge in approval of AI-based platforms are some of the key factors boosting the market growth.
Surge in approval of AI-based platforms is predicted to boost the market growth during the forecast period. Medical examinations like endoscopy, head MRI, CT scans of the sinuses and head, panoramic dental x-rays, dental cone beam CT scans, PET/CT scans, and chest imaging are employed to verify cancer diagnoses and determine the malignancy's spread. The expectation is that regulatory authorities will grant approvals for the growing adoption of these diagnostic techniques. For instance, in October 2022, The FDA has granted approval to Philips for its AI-driven MRI platform designed for the diagnosis of head and neck cancers.
By diagnostic method, diagnostic imaging equipment was the highest revenue-grossing segment in the global head and neck cancer diagnostic market in 2023 owing to growing demand for early diagnosis, rising new product launches, and surge in approvals by regulatory bodies. Additionally, endoscopy screening equipment is predicted to grow at fastest CAGR during the forecast period owing to the rising advancements in endoscopic technologies, growing launch of technologically advanced products, increasing research & development activities, and surge in initiatives by major market players. For instance, in July 2022, The establishment of the International Center for Recurrent Head & Neck Cancer (IReC) is aimed at expediting research efforts and enhancing results for patients. IReC's objectives also include establishing global benchmarks for effective treatment, palliative care, and supportive services for recurrent head and neck cancer, ultimately improving patient outcomes not only in the UK but also on a global scale.
By End-user, Hospitals was the highest revenue-grossing segment in the global head and neck cancer diagnostic market in 2023 owing to rising prevalence of head & neck cancer, increasing adoption of advanced technologies, and growing launch of advanced products. For instance, in October 2022, Global health technology leader, Royal Philips, has introduced two innovative developments in MR-only workflows aimed at enhancing imaging and simulation for radiotherapy of head and neck cancer. Additionally, Diagnostic centres is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for advanced early diagnostic tools, rising technological advancements, and increasing regulatory approvals of novel products.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing adoption of cancer diagnostics, increasing incidences of cancer, rising awareness initiatives regarding the head & neck cancer, surge in new product launches by leading market players. For instance, in August 2022, Viome Life Science has introduced CancerDetect, an in-home testing solution designed to detect oral and throat cancer. This test provides exceptional precision in early cancer detection and prevention, being the sole oral and throat cancer test to achieve a specificity of 95% and a sensitivity of 90%. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing geriatric population, growing use of immunotherapeutic drugs, surge in approvals by regulatory bodies, and rising initiatives by leading market players. For instance, in July 2023, Biocon Foundation has launched the second edition of the India-specific Consensus Guidelines for Head and Neck Cancer (HNC) management, which were developed by the Oral Cancer Task Force (OCTF). This release coincides with World Head and Neck Cancer Day.
Surge in approval of AI-based platforms is predicted to boost the market growth during the forecast period. Medical examinations like endoscopy, head MRI, CT scans of the sinuses and head, panoramic dental x-rays, dental cone beam CT scans, PET/CT scans, and chest imaging are employed to verify cancer diagnoses and determine the malignancy's spread. The expectation is that regulatory authorities will grant approvals for the growing adoption of these diagnostic techniques. For instance, in October 2022, The FDA has granted approval to Philips for its AI-driven MRI platform designed for the diagnosis of head and neck cancers.
By diagnostic method, diagnostic imaging equipment was the highest revenue-grossing segment in the global head and neck cancer diagnostic market in 2023 owing to growing demand for early diagnosis, rising new product launches, and surge in approvals by regulatory bodies. Additionally, endoscopy screening equipment is predicted to grow at fastest CAGR during the forecast period owing to the rising advancements in endoscopic technologies, growing launch of technologically advanced products, increasing research & development activities, and surge in initiatives by major market players. For instance, in July 2022, The establishment of the International Center for Recurrent Head & Neck Cancer (IReC) is aimed at expediting research efforts and enhancing results for patients. IReC's objectives also include establishing global benchmarks for effective treatment, palliative care, and supportive services for recurrent head and neck cancer, ultimately improving patient outcomes not only in the UK but also on a global scale.
By End-user, Hospitals was the highest revenue-grossing segment in the global head and neck cancer diagnostic market in 2023 owing to rising prevalence of head & neck cancer, increasing adoption of advanced technologies, and growing launch of advanced products. For instance, in October 2022, Global health technology leader, Royal Philips, has introduced two innovative developments in MR-only workflows aimed at enhancing imaging and simulation for radiotherapy of head and neck cancer. Additionally, Diagnostic centres is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for advanced early diagnostic tools, rising technological advancements, and increasing regulatory approvals of novel products.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing adoption of cancer diagnostics, increasing incidences of cancer, rising awareness initiatives regarding the head & neck cancer, surge in new product launches by leading market players. For instance, in August 2022, Viome Life Science has introduced CancerDetect, an in-home testing solution designed to detect oral and throat cancer. This test provides exceptional precision in early cancer detection and prevention, being the sole oral and throat cancer test to achieve a specificity of 95% and a sensitivity of 90%. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing geriatric population, growing use of immunotherapeutic drugs, surge in approvals by regulatory bodies, and rising initiatives by leading market players. For instance, in July 2023, Biocon Foundation has launched the second edition of the India-specific Consensus Guidelines for Head and Neck Cancer (HNC) management, which were developed by the Oral Cancer Task Force (OCTF). This release coincides with World Head and Neck Cancer Day.
Segmentation: Head and Neck Cancer Diagnostic Market Report 2022 - 2033
Head and Neck Cancer Diagnostic Market Analysis & Forecast by Diagnostic Method 2023 - 2034 (Revenue USD Bn)
- Endoscopy Screening Equipment
- Dental Diagnostic Methods
- Diagnostic Imaging Equipment
- Bioscopy Screening Tests
- Other
Head and Neck Cancer Diagnostic Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Diagnostic Centres
- Hospitals
- Others
Head and Neck Cancer Diagnostic Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Head and Neck Cancer Diagnostic Market: Diagnostic Method Estimates & Trend Analysis
8. Head and Neck Cancer Diagnostic Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Head and Neck Cancer Diagnostic Market
11. Europe Global Head and Neck Cancer Diagnostic Market
12. Asia Pacific Global Head and Neck Cancer Diagnostic Market
13. Latin America Global Head and Neck Cancer Diagnostic Market
14. MEA Global Head and Neck Cancer Diagnostic Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Fujifilm
- GE Healthcare
- Canon Medical system Corporation
- Philips Healthcare
- Identafi
- Carestream Healthcare
- Addent Inc
- Neusoft Medical
- Siemens Healthineers
- Shimadzu Corporation
- Planet DDS (Apteryx Imaging Inc)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.48 Billion |
| Forecasted Market Value ( USD | $ 18.99 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
